13/07/2026 Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN IQIRVO® demonstrated statistically significant improvement in ALP normalization in patients with PBC in Phase 3b study Q32 Bio announced results from Part B of the Phase 2a study of bempikibart in Alopecia Areata Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN (Ref) Novartis Pharmaceuticals Canada announce

13/02/2026 Novartis announced Phase 3 data in adult patients with IgA nephropathy Novartis announced Phase 3 data in adult patients with IgA nephropathy ( Ref ) Novartis announced final results from its Phase 3 ALIGN/ NCT04573478 study which evaluated Vanrafia (atrasentan; an ETA receptor antagonist) in adult patients with IgA nephropathy (IgAN) The study demonstrated a slowing of kidney function decline in adult patients with IgAN The ALIGN study showed a difference of 2.39